PHA 5128 Spring 2009 First Exam (Version B)
|
|
- Muriel Roberts
- 6 years ago
- Views:
Transcription
1 Name: UFID: PHA 5128 Spring 2009 First Exam (Version B) On my honor, I have neither given nor received unauthorized aid in doing this assignment. Print: Sign: Version B Q1: Phenytoin (10) Q2: procainamide (10) Q3: digoxin (10) Q4: vancomycin (10) Q5: Age (5) Q6: gentamicin (10) Q7: CL (5) Q8: valproic acid (10) Q9: Digoxin (10) Q10: carbamazepine (10) Q11: Methotrexate (10) Total Points: 100
2 Question 1: P.T., a 35-year-old, 74 kg male, had been taking 300 mg/day of phenytoin; However, his dose was increased to 350 mg/day because his seizures were poorly controlled and because his plasma concentration was only 7 mg/l. Now he complains of minor CNS side effects and his reported plasma phenytoin concentration is 22 mg/l. Renal and hepatic function are normal. Assume that both of the reported plasma concentrations represent steady state levels and that P.T. has complied with the prescribed dosing regimens. Calculate P.T. s apparent Vm and Km. A. Vm = 380 mg Km = 1.9 mg/l B. Vm = 1.9 mg Km = 380 mg/l C. Vm = 760 mg Km = 0.9 mg/l D. Vm = 0.9 mg Km = 760 mg/l E. None of the above Initially, 7= Km * 300/ (Vm 300) 7Vm 2100 = Km * Changed 22= Km * 350/ (Vm 350) 22Vm 7700 = Km * Solving 1and 2 Vm = ~ 380 mg And then Km = 1.86 ~ 1.9 mg/l
3 Question 2: B.K., a 65-year-old, 75 kg male, was admitted to the coronary care unit with a diagnosis of acute myocardial infarction. He has a history of mild chronic renal failure, but he does not have CHF. His serum creatinine of 1.5mg/dL. He has developed premature ventricular contractions (PVCs) which were unresponsive to lidocaine. Calculate a parenteral loading dose of procainamide designed to achieve a plasma concentration of around 8 mg/l and an i.v. maintenance infusion rate that will maintain an average plasma concentration of 6mg/L. A. Loading Dose = 1200 mg; Maintenance infusion rate = 184 mg/min B. Loading Dose = 1200 mg; Maintenance infusion rate = 3.1 mg/min C. Loading Dose = 1400 mg; Maintenance infusion rate = 184 mg/min D. Loading Dose = 1400 mg; Maintenance infusion rate = 3.1 mg/min E. Loading Dose = 1200 mg; Maintenance infusion rate = 21.4 mg/hr Vd= 2* 75 = 150 L LD =Cp * Vd / (F * S) = 8 * 150/ (1 * 0.87) = 1379 mg ~ 1400 mg Clcr = (140-65) * 75/ ( 72 * 1.5)= 52.1 ml /min ~ 3.1 L/h Clren = 3 * 3.1 = 9.3 L/h Clacet = 0.13 * 75 = 9.75 L/h Clother = 0.1 * 75 = 7.5 L/h Cltotal = = L/h MD = Cssave * CL * τ /( F* S) = 6 * * 1 / ( 1 * 0.87) = mg/hr ~ 184 mg/hr ~ 3.1 mg/min
4 Question 3: A.H. (55 years old, 58 kg, SrCr = 2.5 mg/dl, female) was admitted to the hospital and was diagnosed with congestive heart failure. She had been taking 0.25 mg digoxin qd for 3 months. The digoxin plasma concentration was determined to be 5 μg/l. How long will it take for the concentration to fall back to 1 μg/l if digoxin therapy was stopped? Pick the closest answer. (10 points) A. 2 days B. 4 days C. 8 days D. 16 days E. 31 days Clcr (female) = (140-55)* 58 / (85* 2.5) = 23.2 ml/min Cl ( CHF patients) = (0.33 *58) + (0.9 *23.2) = 40.0 ml/min ~ 57.6 L/day V = (3.8 * 58) + (3.1 * 23.2) = 292 L k = Cl /V = 57.6 /292 = day -1 t = ln (C1/C2)/ k = ln (5/1)/ = 8.15 days
5 Question 4: H.K., 55 year old, 5 2, 70 kg woman with a serum creatinine of 1.6 mg/dl, has been empirically started on 500 mg of vancomycin every 12 hours for treatment of a staphylococcal infection. What are the expected peak and trough vancomycin concentrations for H.K? (10 points). (Use IV Bolus Equations). A. Css max =26 mg/l Css min = 13.5 mg/l B. Css max =52 mg/l Css min = 27 mg/l C. Css max =13 mg/l Css min = 6.8 mg/l D. Css max =10 mg/l Css min = 5 mg/l E. Css max =13.5 mg/l Css min = 26 mg/l First, the Vd, Cl and ke must be calculated: For the Vd, Vd =0.17(55 years) (70 kg) + 15 = L Creatinine clearance can be used to estimate her clearance, but we must first check if the patient is obese: IBW= *2=50.1 IBW*1.2=50.1*1.2=60.12 Since the patient is obese, we use the ABW for the CL calculation: ABW=IBW + 0.4(TBW-IBW)= (19.9)=58.06 Clcr = (140-55)*58.06 = ml/min = 2.18 L/h ~Cl 85*1.6 Now ke can be determined: Ke = 2.18/39.75 = h -1 Now you can determine peak and trough concentrations Css max = (500/39.75) = mg/l (1 - e *12 ) Css min = 26.03*e *12 = mg/l
6 Question 5: Which combination of the following pharmacokinetic changes best describes the elderly and neonates? (These groups share similar PK characteristics.) 1. Low renal clearance 2. Longer half-lives 3. Low metabolic clearance 4. Decreased protein binding 5. Relatively less body water A. 1 & 4 B. 1, 2, 3& 4 C. 1, 3, 4 &5 D. 1, 4, &5 E. all of the above
7 Question 6: A patient was given 100 mg gentamicin over 30 minutes (i.v.) from 8:30 to 9:00 am. The following two serum levels were measured: 6μg/ml at 9:30 am and 2μg/ml at 4:00 pm. Calculate:a.the peak concentration at 9:00 am, b.the volume of distribution. (assume steady state levels) A. a:6.53 ug/ml, b:19.8l B. a:12.84ug/ml, b: 39.6L C. a:6.53 mg/ml, b:22.2l D. a: 12.84ug/ml, b:39.6l E. a: 25.9 mg/l, b: 65 L
8
9 Question7: Which of the following changes goes along with a decreased clearance and no change in volume of distribution? A. shorter half-life, higher steady state concentration B. longer time to steady state, shorter half-life C. longer time to steady state, lower steady state concentration D. increased initial concentration after an i.v. bolus, longer time to steady state E. longer time to steady state, higher steady state concentration
10 Question 8: C.S., a 10-year-old, 28 kg female, is receiving valproic acid sprinkles 250 mg (2 125mg) po q8hr for her seizure disorder. Calculate her valprioc aicd level at steady state. A. Cp ss_ave = 63mg/L B. Cp ss_ave = 72mg/L C. Cp ss_ave = 80mg/L D. Cp ss_ave = 86mg/L E. Cp ss_ave = 94mg/L Cl = (13mL/kg/hr)(28kg) = 364mL/hr or 0.364L/hr Cp ss_ave = (1)(1)(250mg/8hr)/(0.364L/hr) = mg/l
11 Question 9: Please mark the CORRECT statements about Digoxin. 1) Digoxin is a PGP-substrate. 2) Digoxin follows a one compartment body model. 3) Digoxin levels are increased in patients with hyperthyroid function. 4) Digoxin distributes rapidly into the myocardial tissue. 5) Digoxin is only renally eliminated A. 1, 3, 4 B. 2, 3, 5 C. 1, 2, 3, 4 D. 1, 2, 4, 5 E. None of the above
12 Question 10: Y.T., a 46-year-old, 60 kg female, is to be given carbamazepine as an anticonvulsant agent. Calculate a daily dose of Tegretol XR that will produce an average steady-state plasma concentration of approximately 8mg/L. What would be a reasonable starting dose? A. MD = 800mg/day, start with 200mg twice daily and increase by 200 mg/day in weekly intervals B. MD = 600mg/day, start with 200mg daily and increase by 200 mg/day in weekly intervals C. MD = 600mg/day, start with 300mg twice daily D. MD = 1000mg/day, start with 200mg twice daily and increase by 200 mg/day in weekly intervals E. MD = 1000mg/day, start with 500mg twice daily Css, ave CL τ MD = = = 1053 mg / day 1000 mg / day F S Start with 200mg twice daily and increase by 200 mg/day in weekly intervals until the final dose of 1000mg/day.
13 Questions 11: T.X. is a 53 kg female patient (47 years) to receive methotrexate therapy. Her serum creatinine is 1.2 mg/dl. She is treated with a loading dose (20 mg) followed by an infusion of 25 mg/h over 36 hours. She will then receive a 10 mg/m 2 dose of leucovorin q6h (four doses) followed by eight oral doses (q6h) of 20 mg. Calculate the expected MTX concentration at 60hr after the start of the infusion and the expected time that the methotrexate level will fall below 0.1 μm by using the typical half-life parameters? After the drug sampling report [14 μm (24h), 1.74 μm (48 h), and 0.20 μm (75h)], adjust your prediction according to data. (You can assume the plasma concentration already reached steady state after 24 hrs infusion.) A. Expected: C 60h =0.24uM, t 0.1uM =73 hr; Adjusted: C 60h =0.40uM, t 0.1uM =90 hr B. Expected: C 60h =0.40uM, t 0.1uM =80 hr; Adjusted: C 60h =0.45uM, t 0.1uM =85 hr C. Expected: C 60h =0.75uM, t 0.1uM =88 hr; Adjusted: C 60h =0.55uM, t 0.1uM =82 hr D. Expected: C 60h =0.40uM, t 0.1uM =80 hr; Adjusted: C 60h =0.65uM, t 0.1uM = 88hr E. Expected: C 60h =0.15uM, t 0.1uM =68 hr; Adjusted: C 60h =0.32uM, t 0.1uM =108 hr F. Calculate the expected MTX steady-state concentration (in µm). ( ) CLCr = = 48.3 ml / min 2.9 L / h CL = CL 1.6 = 2.9 L / h 1.6 = 4.64 L / h MTX Cr C ss = R0 25 mg / h 5.39 mg / L 5.39 mg/ L CL = 4.64 L / h = = = um Calculate the predicted concentrations at 24, 48 and 60 h after the start of the MTX infusion. 36 h: µm t 0.5uM 60 h: ln 0.5 = + 36 = = 49.7h ( ) Cp = 0.5uM e = 0.24uM
14 t 0.1µM.5 ln 0.1 = = 72.9h The reported levels were 14 μm (24h), 1.74 μm (48 h), and 0.20 μm (75h) k α 14 ln 1.74 = = 0.174h 12 1 t 0.5uM 14 ln 0.5 = 36 + = 55.2h ln( ) kβ = = h T = 15h Cp60 = 0.4uM and t = 90h 1/2β 0.1uM
15
16
17
18
19
20
21
22
23
PHA 5128 Spring 2000 Final Exam
PHA 128 Spring 2000 Final Exam On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name TYPED KEY Questions Points 1. /1 2. /1 3. /1 4. /1. /10 6. /10. /10 8. /10
More informationPHA 5128 Final Exam Spring 2004 Version A. On my honor, I have neither given nor received unauthorized aid in doing this assignment.
PHA 5128 Final Exam Spring 2004 Version A On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name There are 18 questions. Total /120 pts Final 2004 1 1. T.P., a 66-year-old,
More informationName: UFID: PHA Exam 2. Spring 2013
PHA 5128 Exam 2 Spring 2013 1 Carbamazepine (5 points) 2 Theophylline (10 points) 3 Gentamicin (10 points) 4 Drug-drug interaction (5 points) 5 Lidocaine (5 points) 6 Cyclosporine (5 points) 7 Phenobarbital
More informationPHA Spring First Exam. 8 Aminoglycosides (5 points)
PHA 5128 Spring 2012 First Exam 1 Aminoglycosides (5 points) 2 Aminoglycosides (10 points) 3 Basic Principles (5 points) 4 Basic Principles (5 points) 5 Bioavailability (5 points) 6 Vancomycin (5 points)
More informationPHA Case Studies V (Answers)
PHA 5128 Case Studies V (Answers) 1. A 100 kg patient is to be treated p.o. with sodium phenytoin capsules. Assuming a phenytoin volume of distribution of 0.7 L/kg, Km of 4 mg/l and Vmax of 7 mg/kg/day,
More informationCarbamazepine has a clearance of L/h/kg for monotherapy. For immediate release carbamazepine, the oral bioavailbility is 0.8
PHA 5128 Dose Optimization II, Spring 2013, Case Study IV Solution If you have any questions regarding this case study, do not hesitate to contact Benjamin Weber (benjaminweber@ufl.edu). Please remember
More informationThus, we can group the entire loading dose together as though it was given as a single dose, all administered when the first dose was given.
PHA 5128 Dose Optimization II, Spring 2012, Case Study V Solution If you have any questions regarding this case study, do not hesitate to contact Benjamin Weber (benjaminweber@ufl.edu). Please remember
More informationPHA 5128 CASE STUDY 5 (Digoxin, Cyclosporine, and Methotrexate) Spring 2007
PHA 5128 CASE STUDY 5 (Digoxin, Cyclosporine, and Methotrexate) Spring 2007 1. L.J., a 30 year old male, was diagnosed congestive heart failure (CHF). He is 5'9" tall and weights 80 kg. He was given Furosemide
More information. Although there is a little
PHA 58 Spring 007 Case study 4. Baby girl A, 3kg, 5 days, is receiving phenobarbital because of neonatal seizures. An IV loading dose of phenobarbital sodium of 0mg/kg was given followed by maintenance
More informationPHA Final Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.
PHA 5127 Final Exam Fall 2012 On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name Please transfer the answers onto the bubble sheet. The question number refers
More informationPHA 5127 FINAL EXAM FALL On my honor, I have neither given nor received unauthorized aid in doing this assignment.
PHA 5127 FINAL EXAM FALL 1997 On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name Question Points 1. /14 pts 2. /10 pts 3. /8 pts 4 /8 pts 5. /12 pts 6. /8 pts
More informationPHA Second Exam Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.
PHA 5127 Second Exam Fall 2013 On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name Question/Points Set I 20 pts Set II 20 pts Set III 20 pts Set IV 20 pts Set
More informationTDM of Aminoglycoside Antibiotics
TDM Lecture 3 5 th Stage TDM of Aminoglycoside Antibiotics The aminoglycoside antibiotics are widely used for the treatment of gram-negative infections, often in combination with a β-lactam antibiotic
More informationPHA Final Exam Fall 2006
PHA 5127 Final Exam Fall 2006 On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name Please transfer the answers onto the bubble sheet. The question number refers
More informationPHA5128 Dose Optimization II Case Study 3 Spring 2013
Use the vancomycin dosing nomogram table below: A female patient, 57 years of age, 5 6 in height and 100 in weight had an infection requiring vancomycin treatment. Her serum creatinine was 0.8 mg/d. What
More informationCLINICAL PHARMACOKINETICS INDEPENDENT LEARNING MODULE
CLINICAL PHARMACOKINETICS INDEPENDENT LEARNING MODULE Joseph K. Ritter, Ph.D. Assoc. Professor, Pharmacology and Toxicology MSB 536, 828-1022, jritter@vcu.edu This self study module will reinforce the
More informationPHA 5128 Case Study 4 (Answers) Total Cp = Unbound Cp/fu.
PHA 58 ase Study 4 (Answers) Spring 4. PT is a patient stabilized on chronic phenytoin therapy. She has just been diagnosed with rheumatoid arthritis and her physician would like to start her on high dose
More informationBasic Pharmacokinetic Principles Stephen P. Roush, Pharm.D. Clinical Coordinator, Department of Pharmacy
Basic Pharmacokinetic Principles Stephen P. Roush, Pharm.D. Clinical Coordinator, Department of Pharmacy I. General principles Applied pharmacokinetics - the process of using drug concentrations, pharmaco-kinetic
More informationPHARMACOKINETICS SMALL GROUP II:
PHARMACOKINETICS SMALL GROUP II: Question 1 Why are some drug therapies initiated with a loading dose? Emphasize that LD establishes initial therapeutic level quickly. The time to reach the steady-state
More informationPHA Second Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.
PHA 5127 Second Exam Fall 2011 On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name Put all answers on the bubble sheet TOTAL /200 pts 1 Question Set I (True or
More informationPHA 4120 Second Exam Key Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.
PHA 4120 Second Exam Key Fall 1997 On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name Question Points 1. /10 ponts 2. /20 points 3. /10 points 4. /10 points
More informationPHA Final Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.
PHA 5127 Final Exam Fall 2010 On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name Please transfer the answers onto the bubble sheet. The question number refers
More informationLD = (Vd x Cp)/F (Vd x Cp)/F MD = (Css x CL x T)/F DR = (Css x (Vm-DR))/Km Css = (F x D)/(CL x T) (Km x DR)/(Vm DR)
PHARMKIN WORKSHOP A PHARMACOKINETICS TEACHING SIMULATION Joseph K. Ritter, Ph.D. Associate Professor, Pharmacology and Toxicology MSB 536, 828-1022, jritter@mail2.vcu.edu Tompkins-McCaw Libray Room 2-006
More informationTDM Lecture 7 5 th Stage. TDM of Digoxin. Uses: Digoxin is usually used in heart failure associated and atrial fibrillation.
TDM Lecture 7 5 th Stage TDM of Digoxin Digoxin uses and elimination Uses: Digoxin is usually used in heart failure associated and atrial fibrillation. Elimination: About 75% of digoxin clearance occurred
More informationPHA First Exam Fall 2003
PHA 5127 First Exam Fall 2003 On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name Question/Points 1. /14 pts 2. /6 pts 3. /15 pts 4. /12 pts 5. /20 pts 6. /10pts
More informationPHA Second Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.
PHA 5127 Second Exam Fall 2012 On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name Put all answers on the bubble sheet TOTAL /150 pts 1 Question Set I (True or
More informationTDM of Digoxin. Use of Digoxin Serum Concentrations to Alter Dosages
TDM Lecture 8 5 th Stage TDM of Digoxin Use of Digoxin Serum Concentrations to Alter Dosages Linear Pharmacokinetics Method This method is used in steady-state condition. We compute the new dose of digoxin
More informationAdjusting phenytoin dosage in complex patients: how to win friends and influence patient outcomes
Adjusting phenytoin dosage in complex patients: how to win friends and influence patient outcomes Brian Hardy, PharmD, FCSHP, FCCP Coordinator Education and Clinical Programs Department of Pharmacy Sunnybrook
More informationCase Study 2 Answers Spring 2006
Case Study 2 Answers Spring 2006 1. The volume of distribution of diazepam in a group of normal subjects (60 kg, ideal body weight) was found to be 105 L. In another group of patients (110 kg), the volume
More informationMultiple IV Bolus Dose Administration
PHARMACOKINETICS Multiple IV Bolus Dose Administration ١ Multiple IV Bolus Dose Administration Objectives: 1) To understand drug accumulation after repeated dose administration 2) To recognize and use
More informationSHC Vancomycin Dosing Guide
SHC Vancomycin Dosing Guide A: Initial dosing considerations B. Pharmacodynamic Targets: goal AUC and troughs C. Loading dose D: Initial Vancomycin Maintenance Dosing and Serum Concentration Monitoring
More informationOMCJH.CHEM.COLL.INF.1001 Therapeutic Drug Monitoring Guidelines
OMCJH.CHEM.COLL.INF.1001 Copy of version 1.0 (approved and current) Last Approval or Periodic Review Completed 10/5/2017 Next Periodic Review Needed On or Before 10/5/2019 Effective Date 10/5/2017 Controlled
More informationPHA Final Exam Fall 2001
PHA 5127 Final Exam Fall 2001 On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name Question/Points 1. /12 pts 2. /8 pts 3. /12 pts 4. /20 pts 5. /27 pts 6. /15
More informationDoses Target Concentration Intervention
1 Doses Target Concentration Intervention 2 Problem 1 Questions 1-2 Susan is a 28 year old woman who has had epilepsy since she was 5 years old. She has been on, and off, anticonvulsant medication since
More informationPHARMACOKINETICS SMALL GROUP I:
PHARMACOKINETICS SMALL GROUP I: Question 1 Absorption of the anti-fungal agent, itraconazole, is dependent on a low gastric ph. Calculate the relative concentrations of a weak acid (with a pka of 5.4)
More informationPHA5128 Dose Optimization II Case Study I Spring 2013
Silsamicin is an investigational compound being evaluated for its antimicrobial effect. The route of administration for this drug is via intravenous bolus. Approximately 99.9% of this drug is eliminated
More informationBasic Concepts of TDM
TDM Lecture 1 5 th stage What is TDM? Basic Concepts of TDM Therapeutic drug monitoring (TDM) is a branch of clinical pharmacology that specializes in the measurement of medication concentrations in blood.
More informationPolicy: Created: 2/11/2015; Approved: Adult Pharmacokinetic Dosing and Monitoring- Vancomycin Dosing
ProMedica Health System Clinical Interdepartmental Policy and Procedure: Section: Policy: Date: Subject: Pharmacy Created: 2/11/2015; Approved: Adult Pharmacokinetic Dosing and Monitoring- Vancomycin Dosing
More information1. If the MTC is 100 ng/ml and the MEC is 0.12 ng/ml, which of the following dosing regimen(s) are in the therapeutic window?
Page 1 PHAR 750: Biopharmaceutics/Pharmacokinetics October 23, 2009 - Form 1 Name: Total 100 points Please choose the BEST answer of those provided. For numerical answers, choose none of the above if your
More informationTDM. Measurement techniques used to determine cyclosporine level include:
TDM Lecture 15: Cyclosporine. Cyclosporine is a cyclic polypeptide medication with immunosuppressant effect. It has the ability to block the production of interleukin-2 and other cytokines by T-lymphocytes.
More informationPHA First Exam. Fall 2004
PHA 5127 First Exam Fall 2004 On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name Put all answers on the bubble sheet. If you need to comment or question a problem
More informationMyrna Y. Munar, Pharm.D., BCPS
Phenytoin PK Myrna Y. Munar, Pharm.D., BCPS Associate Professor Clickers Turn clicker on by pressing down menu button Enter you OSU student ID number The up/down diagonal arrows button on the left is the
More informationAMINOGLYCOSIDES TDM D O N E B Y
AMINOGLYCOSIDES TDM DONE BY: SARA ALARFAJ 2014 OUTLINE Introduction about Aminoglycosides. Spectrum/uses. TDM Aminoglycosides TDM Pharmacodynamics Pharmacokinetics. Dosing in AG. Sampeling time and Monitoring.
More informationAminoglycosides. Uses: Treatment of serious gram-negative systemic infections and some grampositive
Aminoglycosides Uses: Treatment of serious gram-negative systemic infections and some grampositive infections such as infective endocarditis. Disadvantage: aminoglycosides are their association with nephrotoxicity
More information4WS Neurology. Table of Contents
4WS Neurology Table of Contents 1. Phenytoin Preparations... Page 2 Monitoring... Page 2 Therapeutic Range... Page 2 Loading Doses... Page 2 Maintenance Doses... Page 3 Sampling Times... Page 3 Dose Adjustment...
More informationPHA Second Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.
PHA 5127 Second Exam Fall 2010 On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name Put all answers on the bubble sheet TOTAL /200 pts 1 Question Set I (True or
More informationTDM. Generally, hepatic clearance is determined by three main factors: These three factors can be employed in the following equation:
Lecture 9: Very important supplements TDM Effect of hepatic disease on drugs monitoring: Generally, hepatic clearance is determined by three main factors: - Liver blood flow (LBF). - Intrinsic capacity
More informationDrug Dosing in Renal Insufficiency. Coralie Therese D. Dimacali, MD College of Medicine University of the Philippines Manila
Drug Dosing in Renal Insufficiency Coralie Therese D. Dimacali, MD College of Medicine University of the Philippines Manila Declaration of Conflict of Interest For today s lecture on Drug Dosing in Renal
More informationA Computer-based Pharmacokinetic Implementation for Digoxin Therapeutic Monitoring in Pediatric Patients
CMU. J. Nat. Sci. (2012) Vol. 11(1) 77 A Computer-based Pharmacokinetic Implementation for Digoxin Therapeutic Monitoring in Pediatric Patients Yupaporn Preechagoon 1 and Peeraya Somsaard 2* 1 Department
More informationpharmacy, we need to see how clinical pharmacokinetics fits into the pharmaceutical care process.
Therapeutic drug monitoring (TDM) Is a tool that can guide the clinician to provide effective and safe drug therapy in the individual patient. Monitoring can be used to confirm a plasma drug concentration
More informationLearning Outcomes. Overall Picture. Part 1 Overview of Key Concepts of Clinical Pharmacokine2cs 4/23/14. A- Awaisu- A- Nader- CPPD
Learning Outcomes CPPD #7 Clinical Pharmacokine2cs: Concepts and Prac2ce Applica2ons Ahmed Nader, Ph.D, BCPS Ahmed Awaisu, Ph.D, B.Pharm Upon comple;on of this session, audience are expected to be able
More informationUSES OF PHARMACOKINETICS
CLINICAL PHARMACOKINETICS Juan J.L. Lertora, M.D., Ph.D. Director Clinical Pharmacology Program Office of Clinical Research Training and Medical Education National Institutes of Health Clinical Center
More informationClinical Pharmacokinetics. Therapeutic Drug Monitoring of Phenytoin
Clinical Pharmacokinetics Therapeutic Drug Monitoring of Phenytoin Dr. Maysa Suyagh School of Pharmacy University of Jordan Phenytoin primarily used as an anticonvulsant and has been used in the treatment
More informationPHAR 7632 Chapter 16
PHAR 7632 Chapter 16 Routes of Excretion Routes of Excretion Student Objectives for this Chapter After completing the material in this chapter each student should:- be able to describe the various routes
More informationUse ideal body weight (IBW) unless actual body weight is less. Use the following equation to calculate IBW:
Amikacin is a partially restricted (amber) antibiotic for the treatment of infections due to gentamicin resistant Gram negative bacilli or as advised by microbiology. As with other aminoglycosides, therapeutic
More information2015 Updates in Therapeutics: The Pharmacotherapy Preparatory Review & Recertification Course Pharmacokinetics: A Refresher Curtis L.
2015 Updates in Therapeutics: The Pharmacotherapy Preparatory Review & Recertification Course Pharmacokinetics: A Refresher Curtis L. Smith, Pharm.D., BCPS Ferris State University Conflict of Interest
More informationBassett Healthcare Clinical Laboratory
Therapeutic Drug Level Collection Guidelines Anti-epileptic drugs (carbamazepine, phenobarbital, phenytoin, primidone, valproic acid) Consider collecting after steady state conditions are reached, i.e.
More informationThe general Concepts of Pharmacokinetics
The general Concepts of Pharmacokinetics What is this jargon? Is it useful? C max, clearance, Vd, half-life, AUC, bioavailability, protein binding F. Van Bambeke, E. Ampe, P.M. Tulkens (Université catholique
More information(Max 2 g) = to nearest 250 mg
Appendix 1 (part 1 of 8): Rubric for competency assessment of pharmacists prescribing and managing vancomycin Empiric Dosing Phase Pts Yes No Data Error OP Did the pharmacist document the indication 2
More informationGeneral Principles of Pharmacology and Toxicology
General Principles of Pharmacology and Toxicology Parisa Gazerani, Pharm D, PhD Assistant Professor Center for Sensory-Motor Interaction (SMI) Department of Health Science and Technology Aalborg University
More informationGeneral Principles of Pharmacology and Toxicology
General Principles of Pharmacology and Toxicology Parisa Gazerani, Pharm D, PhD Assistant Professor Center for Sensory-Motor Interaction (SMI) Department of Health Science and Technology Aalborg University
More informationADME Review. Dr. Joe Ritter Associate Professor of Pharmacology
ADME Review Dr. Joe Ritter Associate Professor of Pharmacology 828-1022 jkritter@vcu.edu What percent of a weak base (pka = 7.5) and weak acid (pka = 3.5) will be respectively ionized in urine of ph 5.5?
More informationAdult Institutional Pharmacokinetics Protocol
Adult Institutional Pharmacokinetics Protocol Policy Title: Clinical Pharmacokinetics (PK) Service Policy Policy Statement: It is the policy of UMHC that PK consult orders (for vancomycin or aminoglycosides)
More informationIV Vancomycin dosing and monitoring Antibiotic Guidelines. Contents. Intro
IV Vancomycin dosing and Antibiotic Guidelines Classification: Clinical Guideline Lead Author: Antibiotic Steering Committee Additional author(s): as above Authors Division: DCSS & Tertiary Medicine Unique
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,900 116,000 120M Open access books available International authors and editors Downloads Our
More informationChapter-V Drug use in renal and hepatic disorders. BY Prof. C.Ramasamy, Head, Dept of Pharmacy Practice SRM College of Pharmacy, SRM University
Chapter-V Drug use in renal and hepatic disorders. BY Prof. C.Ramasamy, Head, Dept of Pharmacy Practice SRM College of Pharmacy, SRM University Estimating renal function An accurate estimation of renal
More informationA REVIEW ON DOSAGE REGIMEN
79 P a g e e-issn: 2248-9126 Vol3 Issue 2 2013 79-89. Print ISSN: 2248-9118 Indian Journal of Pharmaceutical Science & Research www.ijpsrjournal.com A REVIEW ON DOSAGE REGIMEN Ankith Kumar Reddy B*, Subhashis
More informationLippincott Questions Pharmacology
Lippincott Questions Pharmacology Edition Two: Chapter One: 1.Which one of the following statements is CORRECT? A. Weak bases are absorbed efficiently across the epithelial cells of the stomach. B. Coadministration
More informationFull title of guideline INTRAVENOUS VANCOMYCIN PRESCRIBING AND MONITORING GUIDELINE FOR ADULT PATIENTS. control
Full title of guideline Author: Contact Name and Job Title Division and specialty Scope Explicit definition of patient group to which it applies (e.g. inclusion and exclusion criteria, diagnosis) Changes
More informationPharmacokinetic Calculations
Pharmacokinetic Calculations Introduction. Pharmacokinetics involves the relationship between concentration of drug (and its metabolites), measured most often in plasma, drug dosage, and time. A vast majority
More informationPHARMONITOR II. Optimisation of aminoglycosides dosage regimen with pharmacokinetics modeling. Pierre Wallemacq
PHARMONITOR II Optimisation of aminoglycosides dosage regimen with pharmacokinetics modeling Pierre Wallemacq NATIONAL SYMPOSIUM 20 years EEQ Leuven, March 26th 2009 1 Why monitoring of aminoglycosides?
More informationANTIBIOTIC DOSE AND DOSE INTERVALS IN RRT and ECMO
ANTIBIOTIC DOSE AND DOSE INTERVALS IN RRT and ECMO Professor Jeffrey Lipman Department of Intensive Care Medicine Royal Brisbane Hospital University of Queensland NO CONFLICT OF INTERESTS Important concept
More informationTarget Concentration Intervention
1 Target Concentration Intervention Dose Individualization using Monitoring of Patient Response Nick Holford University of Auckland 2 Objectives 1) Appreciate how a target concentration (TC) strategy is
More informationCAT. Dosisaanpassing van antibiotica, toepasbaarheid van beschikbare calculators. Apr. Glynis Frans Supervisor: Prof. Apr.
CAT Dosisaanpassing van antibiotica, toepasbaarheid van beschikbare calculators Apr. Glynis Frans Supervisor: Prof. Apr. Katrien Lagrou 1. What are the current guidelines and recommendations on TDM for
More informationINTRAVENOUS VANCOMYCIN PRESCRIBING AND MONITORING GUIDELINE FOR ADULT PATIENTS
Title of guideline (must include the word Guideline (not protocol, policy, procedure etc) INTRAVENOUS VANCOMYCIN PRESCRIBING AND MONITORING GUIDELINE FOR ADULT PATIENTS Author: Contact Name and Job Title
More informationNonlinear Pharmacokinetics
Nonlinear Pharmacokinetics Non linear pharmacokinetics: In some cases, the kinetics of a pharmacokinetic process change from predominantly first order to predominantly zero order with increasing dose or
More informationZIN EN ONZIN VAN ANTIBIOTICASPIEGELS BIJ NEONATEN
ZIN EN ONZIN VAN ANTIBIOTICASPIEGELS BIJ NEONATEN Anne Smits Fellow neonatologie UZ Leuven Use of antibiotics in neonates 50 European hospitals 23 non-european hospitals Countries n = 14 n = 9 Pediatric
More informationPharmacokinetics Overview
Pharmacokinetics Overview Disclaimer: This handout and the associated lectures are intended as a very superficial overview of pharmacokinetics. Summary of Important Terms and Concepts - Absorption, peak
More informationCLINICAL PHARMACOKINETICS SERVICE & ANTICOAGULATION GUIDELINES
CLINICAL PHARMACOKINETICS SERVICE & ANTICOAGULATION GUIDELINES Pharmacy Services University of Kentucky HealthCare July 2008 (30 th Edition) Editors: Daniel A. Lewis, Pharm.D., BCPS Clinical Pharmacist
More informationNew drugs necessity for therapeutic drug monitoring
New drugs necessity for therapeutic drug monitoring Stephan Krähenbühl Clinical Pharmacology & Toxicology University Hospital Basel kraehenbuehl@uhbs.ch Drugs suitable for TDM Narrow therapeutic range
More informationLessons from recent studies. João Gonçalves Pereira UCIP DALI
Lessons from recent studies João Gonçalves Pereira UCIP DALI 1 Patterns of Antimicrobial Activity Concentration C max Aminoglycosides Cmax/MIC>10 Metronidazol Area under the concentration curve Azithromycin
More informationMEDICATION MONITORING: Pharmacist-Managed Intravenous (IV) Vancomycin Protocol
I. PURPOSE MEDICATION MONITORING: Pharmacist-Managed Intravenous (IV) Vancomycin Protocol To allow standardized pharmacist management of IV vancomycin in the inpatient setting using evidence-based guidelines
More informationContinuous Infusion of Antibiotics In The ICU: What Is Proven? Professor of Medicine Vice-Chairman, Department of Medicine SUNY at Stony Brook
Continuous Infusion of Antibiotics In The ICU: What Is Proven? Michael S. Niederman, M.D. Chairman, Department of Medicine Winthrop-University Hospital Mineola, NY Professor of Medicine Vice-Chairman,
More informationPHA Exam 1. Spring 2013
PHA 5128 Exam 1 Spring 2013 1 Antibiotics (5 points) 2 Body Wight/Pdiatrics (5 points) 3 Rnal Disas (10 points) 4 Aminoglycosids (5 points) 5 Amikacin (10 points) 6 Gntamicin (10 points) 7 Aminoglycosids
More informationJohn E. Murphy, PharmD, FASHP, FCCP
John E. Murphy, PharmD, FASHP, FCCP Professor of Pharmacy Practice and Science and Associate Dean, College of Pharmacy Professor of Clinical, Family, and Community Medicine College of Medicine, The University
More informationOptimizing antifungal dosing regimens. Joseph Meletiadis, PhD, FECMM Assistant Professor of Microbiology
ATHENA 2017 International Conference November 28 30, 2017 Optimizing antifungal dosing regimens Joseph Meletiadis, PhD, FECMM Assistant Professor of Microbiology Clinical Microbiology Laboratory, «Attikon»
More informationPharmacokinetics in Drug Development. Edward P. Acosta, PharmD Professor & Director Division of Clinical Pharmacology Director, CCC PK/PD Core
Pharmacokinetics in Drug Development Edward P. Acosta, PharmD Professor & Director Division of Clinical Pharmacology Director, CCC PK/PD Core Finding new drugs: A crap shoot Clinical Development Phase
More informationClinical Guidelines for Use of Antibiotics. VANCOMYCIN (Adult)
VANCOMYCIN (Adult) Please always prescribe VANCOMYCIN in the Variable Dose Antibiotic section of the EPMA SUPPLEMENTARY drug chart (and add a placeholder on the electronic drug chart). 1 Background Vancomycin
More informationPHENYTOIN DOSING INFORMATION. Adult Dosage
PHENYTOIN DRUGDEX Evaluations DOSING INFORMATION Adult Dosage Normal Dosage Important Note ) Due to the risk of severe hypotension and cardiac arrhythmias, the rate of IV phenytoin administration should
More informationSection 5.2: Pharmacokinetic properties
Section 5.2: Pharmacokinetic properties SmPC training presentation Note: for full information refer to the European Commission s Guideline on summary of product characteristics (SmPC) SmPC Advisory Group
More informationDrug Disposition in Obesity & Protein-Calorie Malnutrition
Drug Disposition in Obesity & Protein-Calorie Malnutrition JBoullata, PharmD, RPh, BCNSP Associate Professor of Pharmacology & Therapeutics -and- Pharmacy Specialist in Nutrition Support University of
More informationGemcitabine + Cisplatin Regimen
Gemcitabine + Cisplatin Regimen Available for Routine Use in Burton in-patient Derby in-patient Burton day-case Derby day-case Burton community Derby community Burton out-patient Derby out-patient Indication
More informationPrinciples of Pharmacokinetics
Principles of Pharmacokinetics Ákos Csomós MD, PhD Associate Professor Institute of Anaesthesia and Critical Care, Semmelweis University, Budapest, Hungary Pharmacokinetics: Very basics How the organ affects
More informationBSWH Pharmacist Continuing Education PART 5: Pharmacotherapy and Pharmacokinetics in Adults: Aminoglycosides and Vancomycin
BSWH Pharmacist Continuing Education 2015 PART 5: Pharmacotherapy and Pharmacokinetics in Adults: Aminoglycosides and Vancomycin Objectives Define basic pharmacodynamic and pharmacokinetic principles Describe
More informationSYNOPSIS. The study results and synopsis are supplied for informational purposes only.
SYNOPSIS INN : LEFLUNOMIDE Study number : HMR486/1037 et HMR486/3503 Study title : Population pharmacokinetics of A77 1726 (M1) after oral administration of leflunomide in pediatric subjects with polyarticular
More informationVANCOMYCIN DOSING AND MONITORING GUIDELINES
VANCOMYCIN DOSING AND MONITORING GUIDELINES NB Provincial Health Authorities Anti-Infective Stewardship Committee Approved: May 2017 GENERAL COMMENTS Vancomycin is a glycopeptide antibiotic with bactericidal
More informationPrecise PK Formally known as T. D. M. S TM
Precise PK Formally known as T. D. M. S. 2000 TM Version v0.15.01.22 For Windows USER MANUAL Copyright 1986-2015 Healthware, Inc. Healthware Inc. 7770 Regents Rd 113-632 San Diego, CA 92122 Phone/FAX :
More informationVancomycin Pharmacokinetics in Normal and Morbidly Obese Subjects
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Apr. 1982, p. 575-58 66484/82/4575-6$2./ Vol. 21, No. 4 Vancomycin Pharmacokinetics in Normal and Morbidly Obese Subjects ROBERT A. BLOUIN,1 LARRY A. BAUER,3* DELWYN
More informationUnderstand the physiological determinants of extent and rate of absorption
Absorption and Half-Life Nick Holford Dept Pharmacology & Clinical Pharmacology University of Auckland, New Zealand Objectives Understand the physiological determinants of extent and rate of absorption
More information